FDA expands Pfizer and Astellas’ Xtandi into castration-resistant prostate cancer
July 16, 2018Sales and Marketing Astellas, Cancer, FDA, Pfizer, US, Xtandi, pharma, prostate cancer
Astellas and Pfizer have revealed that their androgen receptor inhibitor Xtandi (enzalutamide) has received approval from the FDA to expand …
FDA approves first smallpox therapy to defend against bioterrorism
July 16, 2018Sales and Marketing FDA, pharma, smallpox
The FDA has announced that it has awarded marketing authorisation to SIGA Technologies’ TPOXX (tecovirimat) in the first approval of …
European cannabis market set to be worth €115.7 billion by 2028
July 16, 2018Sales and Marketing Europe, Legislation, cannabis, medicinal marijuana
The European cannabis market is set to be worth €115.7 billion by 2028, according to a report released by the …
Indivior shares soar as US judge rules against Dr Reddy
July 16, 2018Sales and Marketing
Shares in the London listed addiction specialist Indivior surged in price today, as the Indian pharmaceutical company Dr Reddy’s Laboratories …
GSK confirms £250m deal to sell experimental drug to Dermavent Sciences
July 13, 2018Medical Communications Dermavent, GSK, Roivant, tapinarof
British company GlaxoSmithKline has announced that it will sell the rights to its experimental dermatology drug, tapinarof, to Roivant Sciences’ …
J&J ordered to pay $4.68 billion to talc-powder plaintiffs
July 13, 2018Medical Communications J&J, JJ, Johnson and Johnson, legal, talc powder
A Missouri jury has ordered the New Jersey-based healthcare company Johnson and Johnson to pay $4.69 billion to 22 women …
Alvogen court case causes Nevada Judge to halt execution
July 13, 2018Medical Communications Alvogen, Nevada, court, execution, lethal injection
A Nevada Judge has temporarily prevented the use of the sedative midazolam, in the execution of the twice convicted killer …
Takeda’s Ninlaro clears Phase 3 endpoint as maintenance therapy in multiple myeloma
July 12, 2018Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma
After making headlines with its mammoth deal to acquire Shire earlier this year, Takeda has emerged with new Phase 3 …
Top Ten most popular articles on Pharmafile.com this week
July 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, Pfizer, Sanofi, Trump, top 10
In the week leading up to Donald Trump’s visit to the United Kingdom, the news has been dominated by the …
Otsuka snaps up Visterra in $430 million deal
July 12, 2018Research and Development, Sales and Marketing Otsuka, Visterra, acquisition, pharma
Otsuka Pharmaceutical has announced it has reached a definitive, board-approved agreement with Visterra to acquire the latter company in an …
AbbVie and Janssen announce failure of cancer drug Imbruvica in Phase 3 trial
July 12, 2018Research and Development AbbVie, Cancer, FDA, Janssen, approval
AbbVie and Janssen have announced that Imbruvica (ibrutinib) failed to achieve the primary endpoint in a late-stage study assessing its …
Pfizer restructures in preparation for potential sell off
July 12, 2018Sales and Marketing Pfizer, bisoimilar, consumer, health
Pfizer has announced plans to reorganise into three separate units through the separation of its consumer health care business from …
Novartis pulls out of antibiotics, cuts 140 staff
July 12, 2018Sales and Marketing Antibiotics, Novartis, pharma, staff cuts
Novartis has announced that it is to terminate its research operations into antibiotics and antivirals in a reorganisation effort that …
NICE approves treatment for rare and deadly childhood cancer
July 11, 2018Sales and Marketing Cancer, NICE, UK, neuroblastoma, pharma
NICE has recommended that monoclonal antibody dinutuximab beta be used in treating high-risk neuroblastoma – a rare and deadly form …
Celgene and Acceleron’s blood disorder drug smashes endpoints at Phase 3
July 11, 2018Research and Development Acceleron, Celgene, beta-thalassemia, luspatercept, pharma
Celgene and Acceleron have lifted the curtain on new Phase 3 data for their erythroid maturation agent (EMA) luspatercept, confirming …
UK Government announces £10m antimicrobial resistance research competition
July 11, 2018Research and Development 10 million, antimicrobial, competition, government, resistance
The UK Government’s Department of Health and Social Care has announced the launch of a £10 million research competition aimed …
EMA survey identifies gaps in pharma industry’s preparedness for Brexit
July 11, 2018Research and Development CAPS, EEA, EMA, brexit, preparedness
An EMA survey has identified gaps in the pharmaceutical industry’s preparedness for Brexit, finding that only 58% of market authorisation …
Wellcome Trust announces £250m fund for high risk ideas
July 11, 2018Research and Development 250 million, Wellcome, britain, leap fund, pharma
The London-based biomedical research charity the Wellcome Trust, Britain’s wealthiest foundation, has announced the launch of a new £250 million …
Trump forces Pfizer to back down and delay price hikes until 2019
July 11, 2018Research and Development, Sales and Marketing Alex Azar, Donald Trump, Ian Read, Pfizer, President trump, Trump, druig pricing, pharma
Trump bared his teeth, and it paid off. Following his call-out of Pfizer after the US pharma giant ignored the …
Syntimmune appoints Pfizer, AbbVie veteran as new CMO
July 10, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, CMO, John Hopkins University, Pfizer, Syntimmune
The Boston-based clinical biotechnology company Syntimmune has appointed Dr Mario Saltarelli as its Chief Medical Officer. Dr Saltarelli will take …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
